Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.62 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.55 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.55 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.55 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.55 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.55 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.55 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.55 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.55 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.55 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1241267 | 0.97 | ARG1 (0.66) | ARG1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL15610738 | 0.97 | ARG1 (0.66) | ARG1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL5515581 | 0.87 | ARG1 (0.62) | ARG1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL4869760 | 0.87 | ARG1 (0.54) | ARG1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL1567292 | 0.85 | ARG1 (0.60) | ARG1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL28637907 | 0.84 | DRD3 (0.60) | ARG1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL27826683 | 0.84 | DRD3 (0.60) | ARG1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL4868897 | 0.83 | ARG1 (0.49) | ARG1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL5509045 | 0.82 | GRIN2D (0.62) | ARG1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL4866632 | 0.82 | ARG1 (0.70) | ARG1GRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7871982-B2 | Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-01-18 | — | — | US | disclosed |
| US-7867980-B2 | Lincosamide derivatives and antimicrobial agents comprising the same as active ingredient | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-01-11 | — | — | US | disclosed |
| US-20100184746-A1 | LINCOSAMIDE DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD | 2010-07-22 | — | — | US | disclosed |
| EP-2166015-A1 | LINCOSAMIDE DERIVATIVE, AND ANTIBACTERIAL AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT | Meiji Seika Kaisha Ltd. (JP) | 2010-03-24 | — | — | EP | disclosed |
| US-20090156512-A1 | potent activity against resistant pneumococci | MEIJI SEIKA KAISHA, LTD. (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-1970377-A1 | LINCOMYCIN DERIVATIVE AND ANTIBACTERIAL AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2008-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156512-A1 | potent activity against resistant pneumococci | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NAT1, NPM1 | ARG1 314/4885GRIN2D 4128/4885GRIN3B 4063/4885 |
| US-20100184746-A1 | LINCOSAMIDE DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | SIRT6, LAS1L, MRPS18A | ARG1 580/4885GRIN2D 4136/4885GRIN3B 4287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.